"For pharmaceutical executives, the lesson is clear: success in obesity will depend not only on science but also on vigilance, payer alignment, cultural reframing, and equitable access." The Evolution of Obesity Drugs: Lessons from a Century of Failures and the GLP-1 Breakthrough Thani Jambulingam, PhD The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic disease, and sparked an industry gold rush
Of course, further investigations in a healthy population are needed to ascertain the role of carnitine in reducing oxidative stress
If there are toddlers under 3 years old at home, abdominal tenderness prevents the mother from bending over to pick up a 30lb child
Acetaminophen (paracetamol) use, measles-mumps rubella vaccination, and autistic disorder: The results of a parent survey
Some researchers prefer weekend mornings when potential side effects interfere less with work obligations